Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2021 | Prostate Cancer | Original Article

[¹⁸F]-JK-PSMA-7 and [¹⁸F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice

Authors: Gaetan Van Simaeys, Gilles Doumont, Coraline De Maeseneire, Nicolas Passon, Simon Lacroix, Cédric Lentz, Arnaud Horion, Corentin Warnier, David Torres, Corentin Martens, Irina Vierasu, Dominique Egrise, Serge Goldman

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2021

Abstract

Purpose

This preclinical study aims to evaluate the extent to which a change in prostate-specific membrane antigen (PSMA) expression of castration-resistant prostate cancer (CRPC) following standard treatment is reflected in [¹⁸F]JK-PSMA-7 PET/CT.

Methods

Castrated mice supplemented with testosterone implant were xenografted with human LNCaP CRPC. After appropriate tumour growth, androgen deprivation therapy (ADT) was carried out by the removal of the implant followed by a single injection of docetaxel (400 μg/20-g mouse) 2 weeks later. [¹⁸F]JK-PSMA-7 PET/CT were performed before ADT, then before and at days 12, 26, 47 and 69 after docetaxel administration. The [¹⁸F]JK-PSMA-7 PET data were compared to corresponding unspecific metabolic [¹⁸F]FDG PET/CT and ex vivo quantification of PSMA expression estimated by flow cytometry on repeated tumour biopsies.

Results

ADT alone had no early effect on LNCaP tumours that pursued their progression. Until day 12 post-docetaxel, the [¹⁸F]JK-PSMA7 uptake was significantly higher than that of [¹⁸F]FDG, indicating the persistence of PSMA expression at those time points. From day 26 onwards when the tumours were rapidly expanding, both [¹⁸F]JK-PSMA7 and [¹⁸F]FDG uptake continuously decreased although the decrease in [¹⁸F]JK-PSMA uptake was markedly faster. The fraction of PSMA-positive cells in tumour biopsies decreased similarly over time to reach a non-specific level after the same time period.

Conclusion

Applying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [¹⁸F]JK-PSMA-7 PET uptake after successive ADT and chemotherapy may be related to downregulation of PSMA expression in dedifferentiated and rapidly proliferating tumour cells.

Available only for authorised users

Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU guidelines: prostate cancer. 2019. Uroweb. https://uroweb.org/guideline/prostate-cancer/.

Cornford P, Bellmunt J, Bolla M, Briers E, Santis MD, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. Elsevier; 2017;71:630–42. https://www.europeanurology.com/article/S0302-2838(16)30469-9/abstract.

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44. https://doi.org/10.1007/s00259-019-04485-3.CrossRefPubMed

Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–34.CrossRefPubMed

Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5.

Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81–4. https://doi.org/10.2967/jnumed.116.181800.CrossRefPubMedPubMedCentral

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2045–54. https://doi.org/10.1007/s00259-018-4079-z.CrossRefPubMedPubMedCentral

Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68 Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med. 2019;60:950–4. https://doi.org/10.2967/jnumed.118.223099.CrossRefPubMed

Onal C, Guler OC, Torun N, Reyhan M, Yapar AF. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:632–41. https://doi.org/10.1007/s00259-019-04581-4.CrossRefPubMed

10.

Ettala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, et al. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:665–73. https://doi.org/10.1007/s00259-019-04635-7.CrossRefPubMed

11.

Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 2020;47:687–94. https://doi.org/10.1007/s00259-019-04674-0.CrossRefPubMed

12.

Zlatopolskiy BD, Endepols H, Krapf P, Guliyev M, Urusova EA, Richarz R, et al. Discovery of 18 F-JK-PSMA-7, a PET probe for the detection of small PSMA-positive lesions. J Nucl Med. 2019;60:817–23. https://doi.org/10.2967/jnumed.118.218495.CrossRefPubMedPubMedCentral

13.

Sedelaar JPM, Dalrymple SS, Isaacs JT. Of mice and men-warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate. 2013;73:1316–25 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009979/.CrossRefPubMedCentral

14.

Jansen BHE, Yaqub M, Voortman J, Cysouw MCF, Windhorst AD, Schuit RC, et al. Simplified methods for quantification of ¹⁸F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. 2019;60:1730–5. https://doi.org/10.2967/jnumed.119.227520.CrossRefPubMed

15.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:96.CrossRefPubMedPubMedCentral

16.

Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380–7.CrossRefPubMed

17.

Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504–17.CrossRefPubMedPubMedCentral

18.

Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369–76.CrossRefPubMed

19.

Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55:1791–8.CrossRefPubMed

20.

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41.CrossRefPubMedPubMedCentral

21.

Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2:23.CrossRefPubMedPubMedCentral

22.

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefPubMed

23.

Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91.CrossRefPubMed

24.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, et al. Intraindividual comparison of 18 F-PSMA-1007 and 18 F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med. 2018;59:1076–80. https://doi.org/10.2967/jnumed.117.204669.CrossRefPubMed

25.

Hohberg M, Kobe C, Krapf P, Täger P, Hammes J, Dietlein F, et al. Biodistribution and radiation dosimetry of [18 F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res. 2019;9:66.CrossRefPubMedPubMedCentral

26.

Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124 I/131 I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92.CrossRefPubMedPubMedCentral

27.

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesová M, Mier W, et al. [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987.CrossRefPubMed

28.

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550.CrossRefPubMed

29.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted -radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4. https://doi.org/10.2967/jnumed.116.178673.CrossRefPubMed

30.

Jennings D, Hatton BN, Guo J, Galons JP, Trouard TP, Raghunand N, et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia. 2002;4(3):255–62. https://doi.org/10.1038/sj.neo.7900225.CrossRefPubMedPubMedCentral

31.

Sánchez BG, Bort A, Mateos-Gómez PA, Rodríguez-Henche N, Díaz-Laviada I. Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase. Cancer Cell Int. 2019;19:54. https://doi.org/10.1186/s12935-019-0769-2.CrossRefPubMedPubMedCentral

32.

Mout L, de Wit R, Stuurman D, Verhoef E, Mathijssen R, de Ridder C, et al. Testosterone diminishes cabazitaxel efficacy and intratumoral accumulation in a prostate cancer xenograft model. EBioMedicine. 2018;27:182–6. https://doi.org/10.1016/j.ebiom.2017.12.024.CrossRefPubMed

33.

Li C, Wang Z, Wang Q, Ka Yan Ho RL, Huang Y, Chow MSS, et al. Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model. Oncotarget. 2017;9(3):3338–52. https://doi.org/10.18632/oncotarget.23235.CrossRefPubMedPubMedCentral

34.

Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The metabolic phenotype of prostate cancer. Front Oncol. 2017;7:131. https://doi.org/10.3389/fonc.2017.00131.CrossRefPubMedPubMedCentral

35.

Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. https://doi.org/10.1002/jcb.10661.CrossRefPubMed

36.

Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate. 2009;69:1579–85. https://doi.org/10.1002/pros.21004.CrossRefPubMed

37.

Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol. 2012;41:2087–92.CrossRefPubMedPubMedCentral

38.

Bakht MK, Lovnicki JM, Tubman J, Stringer KF, Chiaramonte J, Reynolds MR, et al. Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for 18 F-FDG imaging of PSMA-suppressed tumors. J Nucl Med. 2020;61:904–10. https://doi.org/10.2967/jnumed.119.231068.CrossRefPubMedPubMedCentral

39.

Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2:670–6. https://doi.org/10.1016/j.euo.2018.11.007.CrossRefPubMed

40.

Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. Eur J Nucl Med Mol Imaging. 2020;47(8):2040–1. https://doi.org/10.1007/s00259-019-04623-x.CrossRefPubMed

41.

Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A prospective trial of ⁶⁸Ga-PSMA and ¹⁸F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020;26(17):4551–8. https://doi.org/10.1158/1078-0432.CCR-20-0587.CrossRefPubMed

Title: [18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice
Authors: Gaetan Van Simaeys
Gilles Doumont
Coraline De Maeseneire
Nicolas Passon
Simon Lacroix
Cédric Lentz
Arnaud Horion
Corentin Warnier
David Torres
Corentin Martens
Irina Vierasu
Dominique Egrise
Serge Goldman
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-05169-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

[¹⁸F]-JK-PSMA-7 and [¹⁸F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2021

Cardiac transthyretin amyloidosis 99mTc-DPD SPECT correlates with strain echocardiography and biomarkers

Quantification of perivascular inflammation does not provide incremental prognostic value over myocardial perfusion imaging and calcium scoring

Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer

Comparison of MRI, [18F]FDG PET/CT, and 99mTc-UBI 29-41 scintigraphy for postoperative spondylodiscitis—a prospective multicenter study

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT

A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis